Table 1.
Demographic, socioeconomic, and baseline characteristics.
| Eltrombopag (N=51) | rhTPO (N=50) | Control (N=52) | P valuea | |
|---|---|---|---|---|
| Male, n (%) | 29 (56.9) | 30 (60.0) | 31 (59.6) | .941 |
| Age (years), | ||||
| Mean ± SD | 49.1 ± 18.7 | 50.8 ± 15.3 | 48.3 ± 18.2 | .865 |
| Range | 15-86 | 25-87 | 17-80 | |
| Ethnic group, n (%) | 1.000b | |||
| Han | 51 (100.0) | 50 (100.0) | 51 (98.1) | |
| Others | 0 (0.0) | 0 (0.0) | 1 (1.9) | |
| Medical insurance, n (%) | .863b | |||
| Urban employees’ basic medical insurance | 10 (19.6) | 13 (26.0) | 15 (28.8) | |
| Urban residents’ basic medical insurance | 17 (33.3) | 19 (38.0) | 12 (23.1) | |
| New rural cooperative medical system | 7 (13.7) | 5 (10.0) | 9 (17.3) | |
| Mixed medical insurancec | 4 (7.8) | 2 (4.0) | 2 (3.8) | |
| Full coveraged | 2 (3.9) | 4 (8.0) | 3 (5.8) | |
| Otherse | 3 (5.9) | 3 (6.0) | 4 (7.7) | |
| Uninsured | 8 (15.7) | 4 (8.0) | 7 (13.5) | |
| Household income (¥/month)f, n (%) | .949b | |||
| <5000 | 18 (35.3) | 14 (28.0) | 19 (36.5) | |
| 5000-10000 | 10 (19.6) | 15 (30.0) | 15 (28.8) | |
| 10001-15000 | 6 (11.8) | 8 (16.0) | 5 (9.6) | |
| 15001-20000 | 9 (17.6) | 7 (14.0) | 8 (15.4) | |
| >20000 | 5 (9.8) | 3 (6.0) | 3 (5.8) | |
| Unknowng | 3 (5.9) | 3 (6.0) | 2 (3.8) | |
| Education level, n (%) | .606 | |||
| Primary school or lower | 17 (33.3) | 15 (30.0) | 22 (42.3) | |
| Middle school | 14 (27.5) | 13 (26.0) | 10 (19.2) | |
| High school | 12 (23.5) | 15 (30.0) | 9 (17.3) | |
| College or above | 8 (15.7) | 7 (14.0) | 11 (21.2) | |
| Occupation, n (%) | .718 | |||
| Manual workers | 6 (11.8) | 10 (20.0) | 8 (15.4) | |
| Agricultural workers | 9 (17.6) | 6 (12.0) | 10 (19.2) | |
| Self-employed | 14 (27.5) | 8 (16.0) | 9 (17.3) | |
| Managers and professionals | 10 (19.6) | 11 (22.0) | 14 (26.9) | |
| Unemployed | 12 (23.5) | 15 (30.0) | 11 (21.2) | |
| BMI (kg/m2), mean (range) | 21.1 (17.5-26.6) | 21.0 (17.1-26.1) | 20.6 (15.4-27.9) | .521 |
| ECOG score, mean (range) | 2.9 (2-4) | 2.7 (2-4) | 2.9 (2-4) | .063 |
| Time since diagnosis of lymphoma (months), mean (range) | 16.0 (1-120) | 18.0 (1-60) | 14.0 (1-72) | .856 |
| Type of lymphoma, n (%) | 1.000b | |||
| DLBCL | 28 (54.9) | 26 (52.0) | 28 (53.9) | |
| T or B lymphoblastic lymphoma | 7 (13.7) | 7 (14.0) | 8 (15.4) | |
| NK/T-cell lymphoma | 5 (9.8) | 5 (10.0) | 4 (7.7) | |
| PTCL | 3 (5.9) | 4 (8.0) | 4 (7.7) | |
| Burkitt lymphoma | 6 (11.8) | 6 (12.0) | 5 (9.6) | |
| Other typesh | 2 (3.9) | 2 (4.0) | 3 (5.8) | |
| Bone marrow invasion of lymphoma, n (%) | 5 (9.8) | 5 (10.0) | 6 (11.5) | .952 |
| Chemotherapy, n (%) | 1.000b | |||
| CHOP or CDOP ± R | 23 (45.1) | 22 (44.0) | 25 (48.1) | |
| R-EPOCH | 3 (5.9) | 3 (4.0) | 3 (5.8) | |
| R-CODOX-M or R-IVAC | 6 (11.8) | 6 (14.0) | 5 (7.7) | |
| CAM | 3 (5.9) | 4 (8.0) | 4 (7.7) | |
| VDLP | 4 (7.8) | 3 (6.0) | 4 (7.7) | |
| P-Gemox | 5 (9.8) | 5 (10.0) | 4 (9.6) | |
| DICE | 4 (7.8) | 4 (8.0) | 3 (5.8) | |
| Other chemotherapyi | 3 (5.9) | 3 (6.0) | 4 (7.7) | |
| Prior chemotherapy regimens, mean (range) | 6.1 (1-20) | 6.6 (1-19) | 6.9 (1-16) | .518 |
| Radiation therapy, n (%) | 3 (5.9) | 3 (6.0) | 2 (3.9) | .860 |
| Platelet count before chemotherapy (×109/L) | ||||
| Mean ± SD | 135.7 ± 129.1 | 130.3 ± 78.7 | 134.7 ± 87.1 | .512 |
| Range | 5-625 | 7-309 | 8-370 | |
| Leukocyte count (×109/L) | ||||
| Mean ± SD | 2.5 ± 2.7 | 2.5 ± 2.5 | 2.6 ± 3.5 | .469 |
| Range | 0.14-11.19 | 0.05-12.11 | 0.08-16.54 | |
| Hemoglobin (g/L) | ||||
| Mean ± SD | 75.0 ± 18.0 | 78.7 ± 17.7 | 78.7 ± 22.7 | .457 |
| Range | 44-138 | 45-115 | 40-149 | |
| Previous bleedingj, n (%) | 2 (3.9) | 3 (6.0) | 2 (3.8) | .798 |
BMI, body mass index; CAM, cyclophosphamide, cytarabine, mercaptopurine; CDOP ± R, (cyclophosphamide, vincristin, prednisone, adriamycin/liposomal adriamycin) ± rituximab; DICE, dexamethasone, ifosfamide cisplatin etoposide; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; NK/T-cell lymphoma, Natural killer/T-cell lymphoma; P-Gemox, peaspartase, gemcitabine, oxaliplatin; PTCL, peripheral T-cell lymphoma; R-CODOX-M, tuximab, cyclophosphamide, vincristine, adriamycin, methotrexate; R-IVAC, tuximab, ifosfamide, etoposide, arabinoside glycoside; VDLP, prednisone, daunorubicin or liposomal adriamycin, vincristine, pegaspase.
P value compares baseline characteristics among three groups.
Using Fisher’s exact test in R*C table Chi-Square Test.
Two or more insurances, normally indicating the basic insurance plus other supplementary insurances in China.
Medical costs can be almost fully covered.
Other single insurance.
¥5000 equals to US$775, ¥5000-10000 equals to US$775-1550, ¥10001-15000 equals to US$1550-2325, ¥15001-20000 equals to US$2325-3100, ¥20000 equals to US$3100.
Patients either refused to answer the question or did not know the answer.
Other types of lymphoma include marginal area lymphoma, follicular lymphoma and mantle cell lymphoma.
Other chemotherapy include GDP (gemcitabine, cisplatin, dexamethasone), BR (bendamustine, rituximab), and R+MTX (rituximab, methotrexate).
WHO bleeding grades 1 or 2.